Séroussi Brigitte, Bouaud Jacques
Research Mission for Medical Information Science and Technology, Department of Applied Projects, Direction of Information Systems, Assistance Publique-Hôpitaux de Paris, 91 boulevard de l'Hôpital, 75634 Paris 13, France.
Artif Intell Med. 2003 Sep-Oct;29(1-2):153-67. doi: 10.1016/s0933-3657(03)00040-x.
While clinical trials offer cancer patients the optimum treatment, historical accrual of such patients has not been very successful. OncoDoc is a decision support system designed to provide best therapeutic recommendations for breast cancer patients. Developed as a browsing tool of a knowledge base structured as a decision tree, OncoDoc allows physicians to control the contextual instantiation of patient characteristics to build the best formal equivalent of an actual patient. Used as a computer-based eligibility screening system, depending on whether instantiated patient parameters are matched against guideline knowledge or available clinical trial protocols, it provides either evidence-based therapeutic options or relevant patient-specific clinical trials. Implemented at the Gustave Roussy Institute and routinely used at the point of care during a 4-month period, it significantly improved physician compliance with guideline recommendations and enhanced physician awareness of open trials while increasing patient enrollment to clinical trials by 50%. But, when analyzing reasons of non-accrual of potentially eligible patients, it appeared that physicians' psychological reluctance to refer patients to clinical trials, measured during the experiment at 25%, may not be resolved by the simple dissemination of clinical trial information at the point of care.
虽然临床试验为癌症患者提供了最佳治疗方案,但这类患者过去的入组情况并不十分理想。OncoDoc是一个决策支持系统,旨在为乳腺癌患者提供最佳治疗建议。作为一个基于决策树结构的知识库浏览工具开发而成,OncoDoc使医生能够控制患者特征的上下文实例化,以构建实际患者的最佳形式等效物。作为基于计算机的资格筛选系统,根据实例化的患者参数是否与指南知识或可用的临床试验方案相匹配,它提供基于证据的治疗选择或相关的特定患者临床试验。在古斯塔夫·鲁西研究所实施,并在4个月的时间里在护理点常规使用,它显著提高了医生对指南建议的依从性,增强了医生对开放试验的认识,同时使患者参加临床试验的人数增加了50%。但是,在分析潜在合格患者未入组的原因时,发现在实验中测得的医生将患者转介至临床试验的心理抵触率为25%,仅在护理点传播临床试验信息可能无法解决这一问题。